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Abstract
Background: Diagnosis techniques using urine are non-invasive, inexpensive, and easy to perform in clinical
settings. The metabolites in urine, as the end products of cellular processes, are closely linked to phenotypes.
Therefore, urine metabolome is very useful in marker discoveries and clinical applications. However, only univariate
methods have been used in classification studies using urine metabolome. Since multiple genes or proteins would
be involved in developments of complex diseases such as breast cancer, multiple compounds including
metabolites would be related with the complex diseases, and multivariate methods would be needed to identify
those multiple metabolite markers. Moreover, because combinatorial effects among the markers can seriously affect
disease developments and there also exist individual differences in genetic makeup or heterogeneity in cancer
progressions, single marker is not enough to identify cancers.
Results: We proposed classification models using multivariate classification techniques and developed an analysis
procedure for classification studies using metabolome data. Through this strategy, we identified five potential
urinary biomarkers for breast cancer with high accuracy, among which the four biomarker candidates were not
identifiable by only univariate methods. We also proposed potential diagnosis rules to help in clinical decision
making. Besides, we showed that combinatorial effects among multiple biomarkers can enhance discriminative
power for breast cancer.
Conclusions: In this study, we successfully showed that multivariate classifications are needed to precisely
diagnose breast cancer. After further validation with independent cohorts and experimental confirmation, these
marker candidates will likely lead to clinically applicable assays for earlier diagnoses of breast cancer.
Background
Breast cancer is currently the second most common
type of cancer [1] after lung cancer and the fifth most
common cause of cancer death [2]. Therefore, with the
appearance of many high-throughput measurement
technologies, there have been many studies of the diag-
nosis of breast cancer using high-throughput methods
of analysis. Samples for the diagnostic analysis of the
breast cancer include urine, serum, plasma, or tissue,
and various components are measured, including
mRNA, proteome, metabolome, epigenome.
Of the various types of samples, diagnostic techniques
using urine are advantageous in terms of clinical
application to real patients because these techniques are
non-invasive, inexpensive, and easy to perform, likely
leading to earlier detection for malignancies [3]. In addi-
tion, since metabolites are end products of cellular pro-
cesses, their concentrations reflect the systems-level
response of biological systems and are closely linked to
phenotypes and diseases [4]. Urine, moreover, contains
many classes of compounds, including organic acids,
amino acids, purines, pyrimidines, sugars, sugar alcohols,
sugar acids, and amines, which can be diagnostic clues
for a variety of abnormalities. Therefore, urine metabo-
lome is very useful in biomarker discoveries and clinical
applications. However, only univariate methods such as
a t-test, chi-square, and ANOVA have been used in
classification studies using urine metabolome [5-11]. * Correspondence: dhlee@biosoft.kaist.ac.kr
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any medium, provided the original work is properly cited.Principal Component Analysis (PCA) or Partial Least
Squares (PLS) methods, which is a multivariate method,
also has been used, but it is, as a dimension reduction
method, not meant for constructing classification mod-
els, but for visualizing overall distributions of given data
or examining separability between different groups.
Since multiple genes or proteins would be involved in
developments of complex diseases such as breast cancer,
multiple compounds including metabolites would be
related with the complex diseases, and multivariate
methods would be needed to identify those multiple
metabolite markers. Moreover, because combinatorial
effects among the markers can seriously affect disease
developments and there also exist individual differences
in genetic makeup or heterogeneity in cancer progres-
sions, single marker is not enough to identify cancers.
Figure 1 shows multiple components involved in cancers
and combinatorial effects among them. However, there
have been no multivariate classification studies for urine
metabolome data. Although Denkert et al. [12] per-
formed multivariate-based classifications for metabo-
lome data, they used tissue metabolome datasets.
Besides, they did not consider biological implications of
multivariate classifications in the paper.
Therefore, in this study, we proposed classification
models using multivariate classification techniques
(Figure 2) and developed an analysis procedure for clas-
sification studies using metabolome data. (Figure 3)
Through this strategy, we identified five potential urin-
ary biomarkers for breast cancer with high accuracy,
among which the four biomarker candidates were not
identifiable by only univariate methods. (Figure 4, Table
1,2,3) We also proposed potential diagnosis rules to
help in clinical decision making. (Figure 5) Besides, we
showed that combinatorial effects among multiple bio-
markers can enhance discriminative power for breast
cancer. (Figure 6 and 7)
Data
Urine sample collection
Urine samples were collected from female breast cancer
patients (n = 50, age 47.6 ± 7.89 yr) and healthy subjects
as normal controls (n = 50, age 46.64 ± 7.38 yr) at the
Samsung and Hanyang University Medical Centers
(Seoul, Korea). All study subjects underwent the same
diagnostic procedures, i.e., a physical examination of the
breasts, mammography, and ultrasonography as detailed
by the American Joint Committee on Cancer staging.
Figure 1 Potential cases in which multiple proteins are simultaneously related to cancer developments In the case one, two metabolites
should be measured simultaneously to identify cancer. Both metabolites also should be detected in the case two for accurate diagnosis.
Therefore, these cases show that only one metabolite may not be enough for cancer diagnosis.
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cal mastectomy (MRM) or a lumpectomy with an auxili-
ary lymph node dissection. Both pre- and postoperative
urine samples were collected, with the latter obtained 2
weeks after surgery. The sex- and age-matched controls
had no evidence of benign or malignant breast disease.
All of the urine samples were collected in the early
mornings and kept frozen at −20°C until analysis. In
this study, we used only pre-operative and normal sam-
ples to construct models to distinguish between breast
cancer and normal samples.
Sample preparation
Urinary metabolites were prepared by extraction under
four conditions. First, each urine sample (1 mL) was
loaded into a Strata-X cartridge (60 mg, 3 mL; Phe-
nomenox, Torrance, CA), washed with distilled water
(1 mL), and extracted with 4 mL of methanol. The
eluate was divided in half, and one half of the eluate
(2 mL) was evaporated and dried in the desiccator
over 30 min. For the second condition, the other half
of the eluate was evaporated, dissolved in 1 mL of 0.2
M acetate buffer (pH 5.2), and hydrolyzed with b-glu-
curonidase/arylsufatase (50 μL) from Helix Pomatia
(Roche, Mannheim, Germany) at 55°C for 3 hr. After
cooling, urinary metabolites were extracted with 5 mL
of diethyl ether by mechanical shaking for 20 min and
centrifugation at 2500 rpm for 5 min. The separated
organic layer was evaporated under nitrogen and kept
in the desiccator over 30 min. For the third condition,
the remaining aqueous layer was adjusted to pH 1-2
with 200 μL of 3 M HCl and extracted with 5 mL of
diethyl ether. The separated organic extract was evapo-
rated and dried. For the fourth condition, the remain-
ing aqueous layer was adjusted to pH 10 – 11 with
0.73 g of K2CO3 and extracted with 5 mL of diethyl
ether and dried. All dried extracts were derivatized
by 50 μL of MSTFA/TMSI/TMCS (100:2:5, v/v/v)
mixture at 60°C for 15 min and injected into a GC-MS
system.
Figure 2 An overview of the analysis procedure used to construct classification models based on metabolome datasets The procedure
consists of four stages; data standardization, preprocessing, feature selection, and classification. The raw data from mass spectrometry machines
are converted into the standard data formats mzXML [13] and CDF, and in turn preprocessed using the MZmine tool [14,15]. The data are then
analyzed with various feature selection and classification techniques. For feature selection, we use chi-square as a univariate method, the
correlation-based method as a multivariate method, and Decision tree and Random forest as classifier-embedded methods. For classification, we
use Decision tree and Random forest as tree-based non-parametric methods and Support vector machine (SVM) as a generalized linear
discriminative method. (An Artificial neural network (ANN) is not used here, since it is known that the ANN has weak points in many cases,
compared to the SVM [18,19].) The dimension reduction methods PCA and PLS are used for visualizing overall distributions of given data.
Figure 3 A result of partial least square (PLS) for the given
data The datasets are gas chromatography coupled to mass
spectrometry (GC-MS) profiles from urine samples of 50 breast
cancer patients and 50 normal women. The crosses represent
cancer patients, while the asterisks represents normal women. Two
classes are separated well on two principal component axes. This
result suggests a high likelihood that urine samples have
separability between normal women and breast cancer patients.
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All samples prepared were separated through a Ultra-1
capillary column (25 m x 0.2 mm ID, 0.33 μmf i l m
thickness; Agilent, Palo Alto, CA) and analyzed by a
Thermo Finnigan GC-MS system consisting of a Trace
2000 GC and a Polaris Q mass-selective detector in the
scan range of m/z 50 – 800 (Thermo Finnigan, Wal-
tham, MA).
Methods
In this study, we have organized an analysis procedure
to construct classification models based on metabolome
datasets using various multivariate classification meth-
ods. The procedure consists of four stages: data standar-
dization, preprocessing, feature selection, and
classification. (Figure 2)
1) Data standardization stage: raw data from the mass
spectrometry machine is converted into standard
formats. The mzXML [13] and CDF formats are well-
known and used in this work.
2) Preprocessing stage: multiple steps are used to pre-
process raw data, including smoothing, peak detection,
and peak alignment. For those purposes, MZmine soft-
ware [14,15] is suitable and used in this work; this pro-
gram is freeware and is appropriate for liquid
chromatography coupled to mass spectrometry (LC-
MS), gas chromatography coupled to mass spectrometry
(GC-MS), and capillary electrophoresis coupled to mass
spectrometry (CE-MS).
3) Feature selection stage: it is critical in the construc-
tion of classification models and in biomarker discovery
to extract the meaningful variables from among thou-
sands of variables (in this work, m/z peaks). To reflect
various types of distributions of data, we have used a
variety of feature selection algorithms comprising
univariate (t-test and chi-square), multivariate (the
Figure 4 The proposed classification model using the first dataset (Table 1A) This model was constructed by Decision tree. The dataset
consists of three features: M191, M65, and M345. The rectangles represent nodes in a tree, and the box-plots are the corresponding t-test results
of each node, including their p-values, showing the discriminating power of the features.
Table 1 A list of selected feature sets in the feature selection stage
The best feature set (A) The second feature set (B) Univariate-based feature set(C)
Depth of nodes in
Decision Tree
m/z RetentionTime
(sec)
Rank Depth of nodes in
Decision Tree
m/z RetentionTime
(sec)
Rank m/z RetentionTime
(sec)
Rank
0 191.2261 535.3876 1 0 191.2261 535.3876 1 191.2261 535.3876 1
1 65.21586 687.9798 4138 1 93.22983 551.3150 2839 401.1959 781.4042 2
1 345.2603 1483.899 5229 2 147.2395 277.6261 1074 311.2211 783.1188 3
The best feature set (A), the second-best set (B) by the multivariate feature selection method, and a feature set (C) by the univariate method for comparison.
Rank in the feature list from the univariate feature selection is shown.
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Page 4 of 9correlation-based feature selection (CFS) algorithm), and
model-embedded methods (Decision tree [16] and Ran-
dom forest [17]).
4) Classification stage: with selected feature sets, clas-
sification models are constructed. In this work, Decision
tree and Random forest are used as tree-based non-
parametric methods. Support vector machine (SVM) is
used as a generalized linear discriminative method. An
Artificial neural network (ANN) is not used since it is
known that SVM outperforms ANN unless training
datasets are sufficient [18], and ANNt is also weak at
over-fitting and computational complexity because too
many parameters must be estimated [19]. All the algo-
rithms are multivariate.
Table 2 Contingency table for the first feature set
Actual Output Accuracy Sensitivity Specificity
Cancer Normal
Decision Tree
Confidence=0.25 Cancer 47 3 94.00% 94.00% 94.00%
Pruning=true Normal 3 47
Random Forest
Tree=500 Cancer 47 3 95.02% 94.00% 96.00%
Feature=6 Normal 2 48
Support Vector Machine (Linear)
Cost=1 Cancer 50 0 89.06% 100.00% 72.00%
Gamma=0.33 Normal 14 36 # of Support Vectors: 52
Support Vector Machine (Gaussian)
Cost=45 Cancer 49 1 95.16% 98.00% 92.00%
Gamma=0.33 Normal 4 46 # of Support Vectors: 22
Classification results for the first feature set (Table 1A)
Contingency table showing number of cases classified for each of the diagnostic classes for the first feature set (Table 1A).
Table 3 Contingency table for the second feature set
Actual Output Accuracy Sensitivity Specificity
Cancer Normal
Decision Tree
Confidence=0.25 Cancer 46 4 90.06% 92.00% 88.00%
Pruning=true Normal 6 44
Random Forest
Tree=500 Cancer 46 4 91.02% 92.00% 90.00%
Feature=6 Normal 5 45
Support Vector Machine (Linear)
Cost=25 Cancer 48 2 91.41% 96.00% 86.00%
Gamma=0.33 Normal 7 43 # of Support Vectors: 26
Support Vector Machine (Gaussian)
Cost=45 Cancer 46 4 91.02% 92.00% 90.00%
Gamma=0.33 Normal 5 45 # of Support Vectors: 26
Classification results for the second feature set (Table 1B)
Contingency table showing number of cases classified for each of the diagnostic classes for the second feature set (Table 1B).
Kim et al. BMC Bioinformatics 2010, 11(Suppl 2):S4
http://www.biomedcentral.com/1471-2105/11/S2/S4
Page 5 of 9In addition, for visualization of datasets the dimension
reduction algorithms PCA and PLS, are used, allowing
separablity of given datasets to be checked.
Results
Preprocessing of urine metabolome datasets
We have constructed models to classify urine metabo-
lome data into breast cancer and normal, and we have
identified several potential biomarkers for breast cancer,
which are detectable in urine samples, with the meta-
bolome-data analysis procedure described above. First, a
total of 26,306 features, which are m/z valued-peaks
with retention time information, are standardized
through our data converter and then preprocessed by
MZmine (Smoothing, peak detection, peak alignment,
gap-filling, and normalization of the software were
Figure 5 Potential diagnosis rules to help clinical decision making for breast cancer These rules are derived from the classification model
by Decision tree for the first dataset (Table 1A). The values indicate intensities of mass spectrometry of each peak.
Figure 6 The comparison of the performance of univariate versus multivariate classification A t-test, which is a univariate method, has
been applied to the identified feature sets. A) M191 shows a p-value of 2.866e-06 in the t-test, and it seems that this peak can be identified by
both of the univariate and multivariate method. B) However, M65 shows a p-value of 0.7528; therefore this peak cannot be identified by only the
univariate method. In this case, if the multivariate method is applied, then M65 can be identified, because the multivariate method considers
more than two features at the same time and, that is, can find the case that breast cancer and normal samples are classified if two conditions
should be satisfied simultaneously; here, the intensity of M65 is more than 117.6 and the intensity of M191 is less than 168.7. It seems that this
discriminative power of multivariate methods is highly appropriate for biological systems in which more than dozens of factors are able to affect
single disease. As a result, since both conditions are applied together, the criterion becomes strict and the p-value of M65 is dramatically
decreased from 0.7528 (left boxplot; by univariate method) to 5.478e-08 (right boxplot; by multivariate method). C) The p-value for M345 has
also been decreased from 0.4299 (left) to 0.00299 (right).
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m/z value are regarded as different if their retention
times are different.).
Separability analysis using Partial Least Square
Next, to inspect overall distributions of the data, PLS
analysis has been performed (Figure 3). Two classes
have been separated well on two principal component
axes, showing the suitability of the data for this biomar-
ker finding study. Further, these results show that urine
samples contain information that can discriminate
breast cancer from normal, presenting the possibility to
diagnose breast cancer by acquiring and analyzing urine
samples from the patients. The information contained in
the urine samples is likely to be related to the causes of
breast cancer.
Feature selection analysis
Among 26,306 peaks, feature selection has been per-
formed to extract significantly meaningful metabolite
peaks between two groups of people. After many trials
using different feature selection methods, 10 feature sets
have finally been selected by Decision Tree (C4.5 algo-
rithm) [16] in different datasets of 10-fold cross-validation.
Among the 10 feature sets, the best feature set (Table 1A)
and the second set (Table 1B) are shown here. These two
sets consist of five features including one common feature
(191.2261 m/z with 535.3876 retention time). The features
consist of m/z valued-peaks with retention time informa-
tion, and the optimal number of features in each set has
been automatically selected by the C4.5 algorithm, which
has pruning functions to avoid over-fitting. For compari-
son, a feature set (Table 1C) is selected by the univariate
feature selection method (Chi-square), and the ranks in
the feature list from the univariate feature selection are
provided for the three feature sets.
Construction of classification models
Using selected feature sets, classification models have
been constructed through various classification algo-
rithms in our analysis procedure with 10-fold cross-
validation. In both of the two feature sets, overall
accuracies were more than 90 percent. In the first set,
performance, including both sensitivity and specificity,
was more than 94 percent in all of the classifiers except
the linear SVM. (Table 2 and 3) Finally, we have devel-
oped reliable potential diagnosis models for breast can-
cer based on urine samples (Table 1 and Figure 4). In
addition, diagnosis rules to help in clinical decision
making for breast cancer have been proposed from the
models of the Decision Tree (Figure 4 and 5), and these
rules can be useful to clinical applications if the pro-
posed potential biomarkers are confirmed by further
experiments. For performance comparison with univari-
ate classification, three univariate classifiers have been
constructed by each feature of the feature set from the
univariate feature selection using Decision Tree with
only one feature. (Table 4) These results showed that
multivariate classifications outperform univariate meth-
ods by about 6.6~12.7 percent. In addition, as a semi-
multivariate classification, the three features selected by
the univariate feature selection have been applied to
multivariate classification methods to match the number
of features used in the multivariate classifications. How-
ever, in all the classification algorithms, multivariate
classification methods were comparable to or also out-
performed the semi-multivariate approach.
Confirmation of multivariate classification’s power
Last, to confirm the multivariate classification’sp o w e r ,a
t-test, which is a univariate method, has been applied to
the identified feature sets. A metabolite peak of 191.2261
m/z with 535.3876 retention time shows a p-value of
2.866e-06 in the t-test, and it seems that this peak (M191)
can be identified by both the univariate and multivariate
methods (Figure 6A). However, a metabolite peak of
65.21586 m/z with 687.9798 retention time (M65) shows a
p-value of 0.7528, and it seems that this peak cannot be
identified by only the univariate method, given the high
p-value. In this case, if the multivariate method is applied,
then M65 can be identified, because the multivariate
method considers more than two features at the same
Figure 7 M191 causes cancer and M65 and M345 accelerate it In the results, M191 itself had enough discriminative power for breast cancer,
but when it worked together with M65 and M345, the discriminative power was considerably enhanced. This is the second case of the figure 1
and shows that there exists an issue of significant combinatorial effects among multiple metabolites in real dataset analysis.
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univariate feature selection is very low, whose rank is 4138
among 26306 (Table 1A). That is, the multivariate algo-
rithm can find the case that breast cancer and normal
samples are classified if two conditions should be satisfied
simultaneously; in this experiment, the intensity of M65 is
more than 117.6 and the intensity of M191 is less than
168.7. It seems that this discriminative power of multivari-
ate methods is highly appropriate for biological systems in
which more than dozens of factors are able to affect single
disease. (in an algorithmic view, since M191 is a higher
node than M65 in the decision tree of our constructed
classification model, by a split of M191 node, all the
instances are rearranged and divided into two groups so as
to make the lower uncertainty of instance sets at the lower
nodes than M191. Then, in M65 node, classification rules
are searched using only one half of the instances). As a
result, since both conditions are applied together, the cri-
terion becomes strict and the p-value of M65 is dramati-
cally decreased from 0.7528 to 5.478e-08 (Figure 6B). A
metabolite peak of 345.2603 m/z with 1483.899 retention
time (M345) has also been decreased from a p-value of
0.4299 to 0.00299 (Figure 6C).
Discussion
To apply the proposed classification models and poten-
tial biomarkers to real clinical situations, the following
analysis procedures are required:
First, additional validations must be performed using
independent datasets that may have different character-
istics from the data used in this study so as to guarantee
the generality of the proposed models; there have been
a few studies [20-22] performing validations using inde-
pendent datasets. After strict validations, the metabolites
corresponding to the identified peaks, which are the
potential markers, must be identified. In addition, bio-
logical interpretation is required to understand why the
proposed metabolites are significantly different in
patients with breast cancer. This work can be accom-
plished by functional analysis of the metabolic pathways
for the metabolites or enzymes related to them.
However, although further work remains to be done for
actual application in clinical settings, this study proposes
several possibilities for classification and biomarker discov-
ery research using the urine metabolome. The first possi-
bility is that breast cancer can be recognized by analyzing
urine metabolome samples. This becomes more obvious
with the results of partial least square analysis (PLS),
showing that urine samples have the information that can
discriminate between normal and breast cancer groups.
Second, this study shows the possibility that reliable diag-
nosis models and potential markers, whose performance
were all better than 94 percent, can be constructed from
GC-MS urine metabolome datasets. After experimental
validation, the proposed marker candidates will likely lead
to clinically applicable assays for earlier diagnosis of breast
cancer. Furthermore, this study shows the possibility that
multivariate methods can discover ‘hidden features’ that
univariate methods cannot easily find. It seems that this
capability is very important with complex, noisy data, such
as urine metabolome data that may be affected by hetero-
geneity in cancer progression, individual differences of
genetic makeup, or the averaging of multiple characteristic
signals into undistinguishable signals.
Table 4 Contingency table for the feature set from the univariate method
Actual Output Accuracy Sensitivity Specificity
Cancer Normal
M191
Univariate classification Cancer 46 4 87.37% 92.00% 82.00%
Normal 9 41
M401
Univariate classification Cancer 38 12 82.46% 76.00% 88.00%
Normal 6 44
M311
Univariate classification Cancer 40 10 83.12% 80.00% 86.00%
Normal 7 43
M191+M401+M311 (Univariate feature selection + Multivariate classification)
Decision Tree (Confidence=0.25, Pruning=true) 85.01% 86.00% 84.00%
Random Forest (Tree=500, Feature=6) 90.00% 90.00% 90.00%
SVM (Gaussian) (Cost=55, Gamma=0.33, # of SVs=17) 92.27% 96.00% 88.00%
Classification results for the feature set from the univariate method (Table 1C)
Contingency table showing number of cases classified for each of the diagnostic classes for the feature set from the univariate method (Table 1C).
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Diagnostic assays based on urine samples have several
major advantages, including non-invasiveness, inexpen-
siveness, and ease of performance, that will likely lead to
impacts in clinical settings including the earlier detec-
tion of malignancies. As the end products generated by
an organism, metabolites are closely linked to pheno-
types and can be diagnostic clues regarding abnormal-
ities. In this study, we have proposed analysis
procedures using multivariate classification to more pre-
cisely analyze these urine metabolome data. By using
multivariate classification methods, we were able to
more effectively analyze urine metabolome datasets for
which univariate analysis is not powerful enough due to
the data’s complexity. We have found in our experi-
ments that this multivariate approach can identify fea-
tures that are not recognizable by univariate methods.
In conclusion, we have proposed classification models
and five potential urinary biomarkers for breast cancer
diagnosis. Our findings will be helpful in real clinical
settings if additional validations and experimental con-
firmations are performed.
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